ChitogenX (CHGX) AI Stock Analysis

• Market Cap: C$415.65K
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 83,129,520
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 0.05
• Price to Book (P/B): -1.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: ― N/A
• Price Target: ―
• Action: N/A Date: ―
• Date: Action: N/A ―

ChitogenX Business Overview & Revenue Model

Company Description

ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Orth...

Read more

ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Orth...

How the Company Makes Money

ChitogenX makes money through the development, licensing, and sales of its proprietary medical products and technologies. The company's primary revenue streams include direct sales of its chitosan-based products to healthcare providers and institu...

Read more

ChitogenX makes money through the development, licensing, and sales of its proprietary medical products and technologies. The company's primary revenue streams include direct sales of its chitosan-based products to healthcare providers and institu...

ChitogenX Financial Statement Overview

Breakdown	TTM	Apr 2024	Apr 2023	Apr 2022	Apr 2021	Apr 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-18.00K	-42.00K	-59.00K	-69.00K	-89.00K	-119.00K
EBITDA	-1.19M	-670.00K	-4.75M	-3.44M	-2.54M	-2.06M
Net Income	-1.55M	-1.55M	-6.23M	-4.92M	-3.77M	-2.49M
Balance Sheet
Total Assets	385.00K	534.00K	738.00K	1.12M	3.28M	1.29M
Cash, Cash Equivalents and Short-Term Investments	48.00K	35.00K	108.00K	313.00K	2.38M	302.00K
Total Debt	4.23M	3.88M	5.56M	5.71M	4.62M	2.61M
Total Liabilities	7.75M	6.71M	10.58M	8.23M	5.08M	3.69M
Stockholders Equity	-7.36M	-6.18M	-9.84M	-7.10M	-1.80M	-2.40M
Cash Flow
Free Cash Flow	-153.00K	-1.01M	-3.20M	-3.25M	-2.98M	-1.59M
Operating Cash Flow	-153.00K	-1.01M	-3.20M	-3.22M	-2.98M	-1.59M
Investing Cash Flow	0.00	0.00	0.00	-33.00K	-3.00K	0.00
Financing Cash Flow	75.00K	937.00K	2.94M	1.16M	5.05M	1.37M

ChitogenX Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• MACD: Neutral
• RSI: Negative
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CHGX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CHGX.

ChitogenX Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CHGX	―	C$415.65K	―	21.10%	―	―	―
COV	62 Neutral	C$53.58M	95.68	3.31%	―	-9.04%	-80.68%
MBX	45 Neutral	C$35.33M	-6.85	-8.01%	―	-27.23%	-315.49%
HEM	44 Neutral	C$11.87M	-7.36	―	―	―	-24.89%
KNE	44 Neutral	C$6.36M	-2.38	―	―	―	―